Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Trends 2021 | Global Size, Share, Drivers, Competitors Strategy, Regional Analysis and Growth by Forecast to 2026

SEATTLE, April 09, 2021, (PHARMIWEB) — Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market

Exocrine pancreatic insufficiency (EPI) is a condition associated with deficiency of exocrine pancreatic enzymes that results in the inability to digest food or indigestion. EPI may be associated with certain diseases and conditions that affect the pancreas such as cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and others. Chronic pancreatitis (CP) is the most common cause of EPI in adults that is followed by cystic fibrosis (CF). CF is an inherited genetic condition that leads to chronic diseases, which affects lungs, digestive, and reproductive system. Patients suffering from exocrine pancreatic insufficiency cannot properly digest proteins, fats, and carbohydrates in the food that results in poor absorption of nutrients in the body.

For More Information, Request sample copy of Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2020

Furthermore, EPI is associated with uncomfortable gastrointestinal (GI) symptoms, such as bloating, gas, and oily diarrhea, which floats and is difficult to flush. The symptoms of EPI may be similar to other gastrointestinal disorders such as Crohn’s disease, celiac disease, irritable bowel syndrome (IBS), ulcerative colitis, and small intestinal bacterial overgrowth (SIBO), which makes EPI difficult to diagnose. However, there are three major tests used for diagnosis of EPI that include, fecal elastase test, fecal fat test, and direct pancreatic function test.

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Insights

Exocrine pancreatic insufficiency is associated with certain diseases and conditions such as chronic pancreatitis, cystic fibrosis, pancreatectomy, pancreatic cancer, gastrointestinal surgery, type I and type III C diabetes, and other conditions including autoimmune pancreatitis, celiac disease, and inflammatory bowel disease. In addition, the high prevalence of these conditions leads to EPI, which in turn, fuels the growth of the global exocrine pancreatic insufficiency (EPI) therapeutics market. According to a 2010 report by the Cystic Fibrosis Foundation, around 1,000 new cases of cystic fibrosis are diagnosed globally every year.

The American Lung Association reported that cystic fibrosis is the second most inherited disorder in infants in the U.S. The report further stated that around 10 million cases in the U.S are symptomless carriers of the defective cystic fibrosis gene and around 3,708 deaths were reported due to cystic fibrosis between 1999 and 2006. Moreover, pancreatic cancer is a major factor that leads to EPI.  According to a survey conducted by Cancer Research UK in 2015, around 9,800 new pancreatic cancer cases were registered in the U.K. annually, from 2013 to 2015. The report further stated that pancreatic cancer is the eleventh most common cancer in the U.K. that accounted for 3% of all new cancer cases, in 2015.

According to a report issued by the Diabetes.co.uk, 2018, EPI was more evident in the people with insulin-dependent diabetes. According to the same source, in 2003, a study conducted on around 1,000 diabetic patients found that insulin-dependent diabetes was more likely to produce abnormally low levels of exocrine pancreatic enzymes. Furthermore, around 25%-50% of insulin-dependent diabetic patients were found to have developed exocrine pancreatic insufficiency. Moreover, a high prevalence of diabetes may increase the risk of EPI. For instance, according to International Diabetes Federation (IDF) Diabetes Atlas, the number of people with diabetes, worldwide, aged between 20 to 79 years in 2017 was around  425 million, and the number is estimated to increase to 48% in 2045.

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market – Regional Outlook

North America is expected to dominate the global exocrine pancreatic insufficiency (EPI) therapeutics market due to increasing incidence and prevalence cases of these conditions occurring in this region. EPI is mostly characterized with its associated conditions such as cystic fibrosis, pancreatic cancer, chronic pancreatitis, gastrointestinal surgery, and others.

Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2020

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market – Competitive Analysis

The most prominent players operating in the global exocrine pancreatic insufficiency (EPI) therapeutics market include AbbVie, Inc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., Anthera Pharmaceuticals, Inc., Allergan Plc, AzurRx BioPharma, Inc., and numerous others. These players are deeply focused on product regulatory approvals and acquisition strategies to enhance their share in the global market. For instance, in May 2013, AbbVie, Inc. announced the availability of CREON (pancrelipase) 36,000 Lipase-unit Capsules for patients with EPI in the U.S. Furthermore, in May 2018, VIVUS, Inc. entered into definitive agreement with Janssen Pharmaceuticals, Inc. to acquire all the product rights for PANCREAZE (pancrelipase) delayed-release capsules in the U.S. and Canada.

Market Taxonomy

By Disease Management,

• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)

By Therapeutic Drug,

• Creon
• Zenpep
• Pancreaze
• Ultresa
• Viokace
• Others

By Region,

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837